Page 201 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 201
Table S1. Treatment schedule of R2CHOP.
Agent
Day 1
Day 1-5 Day 1-14 Day 2
Dose/day
Cyclophosphamide Vincristine Doxorubicin Rituximab Prednisone Lenalidomide Pegfilgrastim
Route of administration Days
750 mg/m2 i.v. 1.4 mg/m2 (max 2 mg) i.v. 50 mg/m2 i.v. 375 mg/m2 i.v. 100 mg p.o. 15 mg p.o. 6 mg s.c.
R-CHOP with lenalidomide in MYC+ LBCL
References
1. Chamuleau M, Nijland M, Lamers N, et al. First Report on a Successful Screening Program for MYC Rearrangements and a Prospective Clinical Trial Based on MYC Rearrangement in Newly Diagnosed DLBCL Patients in the Netherlands. Blood. 2017; 130(Suppl 1): 4144.
2. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014; 123(8): 1214-1217.
3. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014; 32(27): 3048-3058.
4. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27): 3059-3068.
5. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42(2): 328-354.
6. Jung SH, Kim KM. On the estimation of the binomial probability in multistage clinical trials. Statistics in medicine. 2004; 23(6): 881-896.
7. Koyama T, Chen H. Proper inference from Simon’s two-stage designs. Statistics in medicine. 2008; 27(16): 3145-3154.
8. Kieser M WM, Englert S, Kunz CU and Rauch G. “OneArmPhaseTwoStudy: An R Package for Planning, Conducting, and Analysing Single-Arm Phase II Studies.”. Journal of Statistical Software. 2017; 81(8): 1-28
The R2CHOP schema consist of R-CHOP21 with lenalidomide 15 mg on 1-14. Additionally, patients received at least 4 intrathecal administrations of methotrexate or cytarabine.
199
7
